Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation.
|
| Abstract |
This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV+ patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV+ patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV+ and particularly in CMV+ patients must be discarded.
|
|---|---|
| Authors | Olga Millán, Jordi Rovira, Lluis Guirado, Cristina Espinosa, Klemens Budde, Claudia Sommerer, Gaston J Piñeiro, Fritz Diekmann, Mercè Brunet |
| Journal | Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 229 Pg. 108792 (08 2021) ISSN: 1521-7035 [Electronic] United States |
| PMID | 34217849 (Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't) |
| Copyright | Copyright © 2021 Elsevier Inc. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!